LB PHARMACEUTICALS INC (LBRX) Form 424B3 — Jul 22, 2026
LB Pharmaceuticals Inc announced the accelerated timing of topline results from the Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia. The company disclosed this event in a Current Report on Form 8-K dated July 22, 2026, which is incorporated by reference into this prospectus supplement. As of July 21, 2026, the last reported sale price of the company's common stock was $32.31 per share. The common stock is listed on The Nasdaq Global Market under the symbol LBRX.
Key figures
- Trial Name
- NOVA-2
- Share Price
- $32.31
- Trial Phase
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.